Clinical Research & Data, AMI Cardiogenic Shock



William O’Neill, MD, reviews RECOVER III study data showing improved outcomes associated with best practices, notably, improved survival in patients with AMI cardiogenic shock associated with adoption of best practice protocols in post-PMA vs pre-PMA cohorts:

Earlier shock recognition and initiation of Impella support

Less use of inotropes and vasopressors

More Impella pre-PCI and complete revascularization

More use of right heart catheterization (RHC) to optimize therapy

These led to a lower incidence of adverse events:

Less acute renal failure

Less bleeding requiring transfusion

Fewer vascular complications requiring surgery

Dr. O’Neill also introduces the RECOVER IV study, a randomized controlled trial in which patients with AMI cardiogenic shock will be randomized to the active treatment group using the National Cardiogenic Shock Initiative (NCSI) study protocol, or the control group, in which the patient will be treated with other treatment approaches, including any kind of circulatory support other than the Impella® heart pump.

Dr. O’Neill is the medical director of the Center for Structural Heart Disease, Henry Ford System, Detroit, Michigan.



View more resources